TGNA Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Transgene SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.11 |
52 Week High | €2.15 |
52 Week Low | €1.01 |
Beta | 0.71 |
1 Month Change | 4.52% |
3 Month Change | -18.98% |
1 Year Change | -40.00% |
3 Year Change | -56.04% |
5 Year Change | -60.64% |
Change since IPO | -97.41% |
Recent News & Updates
Recent updates
Shareholder Returns
TGNA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 3.3% | 1.6% |
1Y | -40.0% | 35.8% | 6.4% |
Return vs Industry: TGNA underperformed the German Biotechs industry which returned 35.8% over the past year.
Return vs Market: TGNA underperformed the German Market which returned 6.4% over the past year.
Price Volatility
TGNA volatility | |
---|---|
TGNA Average Weekly Movement | 5.5% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TGNA's share price has been volatile over the past 3 months.
Volatility Over Time: TGNA's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 143 | Alessandro Riva | https://www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene SA Fundamentals Summary
TGNA fundamental statistics | |
---|---|
Market cap | €111.23m |
Earnings (TTM) | -€33.43m |
Revenue (TTM) | €8.91m |
12.5x
P/S Ratio-3.3x
P/E RatioIs TGNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TGNA income statement (TTM) | |
---|---|
Revenue | €8.91m |
Cost of Revenue | €31.56m |
Gross Profit | -€22.65m |
Other Expenses | €10.78m |
Earnings | -€33.43m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 27, 2024
Earnings per share (EPS) | -0.33 |
Gross Margin | -254.29% |
Net Profit Margin | -375.29% |
Debt/Equity Ratio | 52.3% |
How did TGNA perform over the long term?
See historical performance and comparison